Neurosense Therapeutics LTD. (NRSNW) — SEC Filings

Overview

Neurosense Therapeutics LTD. (NRSNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 8, 2025: NeuroSense Therapeutics Ltd. announced on December 8, 2025, that the database for its Phase 2 clinical trial of PrimeC in Alzheimer's disease, the RoAD study, has been locked. This milestone allows for final statistical analyses, with topline results anticipated in the first quarter of 2026. The com

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 19 bullish, 1 bearish, 29 neutral, 1 mixed. The dominant filing sentiment for Neurosense Therapeutics LTD. is neutral.

Filing Type Overview

Neurosense Therapeutics LTD. (NRSNW) has filed 48 6-K, 1 20-F, 1 SC 13G with the SEC between Jun 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Dec 22, 2025
• NeuroSense Locks Alzheimer's Trial Data, Results Due Q1 2026 — 6-K · Dec 8, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. announced on December 8, 2025, that the database for its Phase 2 clinical trial of PrimeC in Alzheimer's disease, the RoAD study, h
• 6-K Filing — 6-K · Dec 4, 2025
• NeuroSense Gets FDA Green Light for ALS Phase 3 Trial — 6-K · Nov 24, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. announced on November 24, 2025, that it has received FDA clearance to initiate a pivotal Phase 3 trial for its drug PrimeC, intende
• NeuroSense Therapeutics Files 6-K with Proxy Statement — 6-K · Nov 21, 2025 Risk: low
  NeuroSense Therapeutics Ltd. filed a Form 6-K on November 21, 2025, to report information for the month of November 2025. The filing includes Exhibit 99.1, whic
• NeuroSense's PrimeC Shows Alzheimer's Biomarker Reduction — 6-K · Oct 6, 2025 Risk: medium
  On October 6, 2025, NeuroSense Therapeutics Ltd. announced that its drug candidate, PrimeC, demonstrated statistically significant reductions in Alzheimer's dis
• NeuroSense Therapeutics Shareholders Approve All Proposed Resolutions — 6-K · Sep 25, 2025 Risk: low
  NeuroSense Therapeutics Ltd. held its Annual General Meeting of Shareholders on September 25, 2025. All resolutions presented to the shareholders, which were pr
• NeuroSense Alzheimer's Drug Shows Early Promise — 6-K · Sep 10, 2025 Risk: medium
  On September 10, 2025, NeuroSense Therapeutics Ltd. announced that its drug candidate demonstrated early signs of efficacy in Alzheimer's patient-derived neuron
• NeuroSense Therapeutics Ltd. Private Placement — 6-K · Sep 4, 2025 Risk: medium
  On September 4, 2025, NeuroSense Therapeutics Ltd. entered into a Securities Purchase Agreement with a single investor to issue and sell 333,334 ordinary shares
• NeuroSense: PrimeC Shows 18-Month ALS Efficacy in New Analysis — 6-K · Sep 2, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. announced on September 2, 2025, a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC for ALS. The analysis sh
• NeuroSense Therapeutics Ltd. Files August 2025 6-K Report — 6-K · Aug 21, 2025 Risk: low
  NeuroSense Therapeutics Ltd. filed a Form 6-K on August 21, 2025, reporting information for the month of August 2025. The company, based in Herzliya, Israel, is
• NeuroSense ALS Drug PrimeC Shows Long-Term Safety in Phase 2a — 6-K · Aug 20, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. reported on August 20, 2025, that approximately 20% of ALS patients from their Phase 2a study, who are continuing on compassionate
• NeuroSense Therapeutics Ltd. Files H1 2025 Business Update — 6-K · Aug 1, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. filed a Form 6-K on August 1, 2025, reporting on its business update for the first half of 2025. The filing includes condensed inte
• NeuroSense Therapeutics Posts Q2 2025 Update Video — 6-K · Jul 10, 2025 Risk: low
  On July 10, 2025, NeuroSense Therapeutics Ltd. released a corporate video titled "End of Q2/2025 Update." This video, available on their investor relations webs
• NeuroSense Completes Health Canada Meeting for ALS Drug — 6-K · Jun 26, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. announced on June 26, 2025, that it has completed a pre-New Drug Submission (pre-NDS) meeting with Health Canada for PrimeC, a pote
• NeuroSense Completes PrimeC Manufacturing Scale-Up — 6-K · May 7, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. announced on May 7, 2025, the successful completion of commercial manufacturing scale-up for its drug candidate, PrimeC. This miles
• NeuroSense Therapeutics Ltd. Updates Shareholders on Progress — 6-K · Apr 24, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. issued a press release on April 24, 2025, providing shareholders with an update on its clinical progress, regulatory strategy, and
• NeuroSense Therapeutics Files 2024 Annual Report — 20-F · Apr 7, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel, is focused o
• NeuroSense Therapeutics Update on Pharma Deal Talks — 6-K · Mar 27, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. provided an update on its binding term sheet with a global pharmaceutical company, originally announced on December 23, 2024. Discu
• NeuroSense Advances PrimeC for ALS in Canada — 6-K · Mar 19, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. has received an invitation from Health Canada for a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Comp
• NeuroSense Therapeutics Reports New ALS Study Data — 6-K · Feb 19, 2025 Risk: medium
  NeuroSense Therapeutics Ltd. announced additional findings from its 18-month Phase 2b PARADIGM study of PrimeC for Amyotrophic Lateral Sclerosis (ALS). The repo
• NeuroSense Therapeutics Regains Nasdaq Compliance — 6-K · Jan 6, 2025 Risk: medium
  On January 6, 2025, NeuroSense Therapeutics Ltd. announced it has regained compliance with Nasdaq's minimum equity requirement. The company is now in compliance
• NeuroSense Therapeutics Advances PrimeC for ALS — 6-K · Dec 23, 2024 Risk: medium
  On December 23, 2024, NeuroSense Therapeutics Ltd. announced it has entered into a binding term sheet to advance its drug candidate PrimeC for Amyotrophic Later
• NeuroSense Therapeutics Ltd. Reports Q3 2024 Results — 6-K · Dec 18, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. filed a Form 6-K on December 18, 2024, to report its business update and third quarter 2024 financial results. The company, headqua
• NeuroSense Therapeutics Faces Nasdaq Delisting Warning — 6-K · Dec 17, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. received a written notice from Nasdaq on June 21, 2024, stating it had not regained compliance with the minimum stockholders' equit
• NeuroSense Gets FDA Nod on PrimeC Phase 3 Study Design — 6-K · Dec 11, 2024 Risk: medium
  On December 11, 2024, NeuroSense Therapeutics Ltd. announced it received positive feedback from the FDA regarding the design of its Phase 3 study for PrimeC. Th
• SC 13G Filing — SC 13G · Dec 9, 2024
• NeuroSense Completes PARADIGM Study, PrimeC Shows ALS Benefits — 6-K · Dec 4, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on December 4, 2024, the completion of its PARADIGM study. The study highlighted significant efficacy and survival benefi
• NeuroSense Therapeutics Ltd. Private Placement Deal — 6-K · Dec 2, 2024 Risk: medium
  On December 2, 2024, NeuroSense Therapeutics Ltd. entered into a Securities Purchase Agreement with a single investor and its CEO, Alon Ben-Noon. The agreement
• NeuroSense Therapeutics Gets Nasdaq Continued Listing Approval — 6-K · Nov 12, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. received a written notice on November 11, 2024, from The Nasdaq Stock Market stating that the Nasdaq Hearings Panel has granted the
• NeuroSense Therapeutics Secures Up to $15M Equity Line — 6-K · Oct 31, 2024 Risk: medium
  On October 31, 2024, NeuroSense Therapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). This agreement allows NeuroS
• NeuroSense Completes 18-Month ALS Trial Dosing — 6-K · Oct 30, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced the completion of 18-month dosing in its PARADIGM Phase 2b ALS clinical trial, with the Last Patient Last Visit occurring
• NeuroSense FDA Meeting Boosts ALS Trial and NDA Path — 6-K · Oct 28, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on October 28, 2024, that it has secured a key meeting with the U.S. Food and Drug Administration (FDA). This meeting is
• NeuroSense PrimeC Shows miRNA Improvement in ALS Patients — 6-K · Oct 24, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on October 24, 2024, that a new analysis of their drug PrimeC showed significant improvement in key microRNAs (miRNAs) in
• NeuroSense Advances ALS Treatment Commercialization in Canada — 6-K · Oct 15, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on October 15, 2024, that it is advancing plans for the early commercialization of its ALS treatment in Canada. The compa
• NeuroSense Plans Early ALS Treatment Commercialization in Canada — 6-K · Oct 9, 2024 Risk: medium
  On October 9, 2024, NeuroSense Therapeutics Ltd. announced its intention to file for early commercialization of its ALS treatment in Canada. This strategic move
• NeuroSense Therapeutics Files 6-K with Financials — 6-K · Sep 30, 2024 Risk: low
  NeuroSense Therapeutics Ltd. filed a Form 6-K on September 30, 2024, reporting its condensed interim unaudited financial statements as of June 30, 2024. The fil
• NeuroSense Regains NASDAQ Compliance, Secures ALS Drug Patent — 6-K · Sep 24, 2024 Risk: medium
  On September 24, 2024, NeuroSense Therapeutics Ltd. announced it has regained compliance with the NASDAQ minimum bid price rule. Additionally, the company was g
• NeuroSense Therapeutics Starts HIPAA Compliance Process — 6-K · Sep 16, 2024 Risk: low
  NeuroSense Therapeutics Ltd. announced on September 16, 2024, that it has officially begun the process of complying with HIPAA regulations. This move is a signi
• NeuroSense Therapeutics Completes Key Toxicity Study Phase — 6-K · Sep 9, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on September 9, 2024, the successful completion of the in-life phase of its nine-month non-rodent toxicity study. This st
• NeuroSense Therapeutics Gets Nasdaq Minimum Bid Price Notice — 6-K · Aug 30, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on August 30, 2024, that it received a notification from Nasdaq regarding its minimum bid price. The company must regain
• NeuroSense in talks for PrimeC drug partnership — 6-K · Aug 28, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. announced on August 28, 2024, that it is in advanced, non-binding discussions with several multi-billion-dollar pharmaceutical comp
• NeuroSense Therapeutics Faces Nasdaq Compliance Hearing — 6-K · Aug 26, 2024 Risk: medium
  NeuroSense Therapeutics Ltd. received a notice on June 21, 2024, that it had not regained compliance with Nasdaq's Listing Rule 5550(b) because its stockholders
• NeuroSense Therapeutics Signs Sales Agreement with JonesTrading — 6-K · Aug 16, 2024 Risk: medium
  On August 16, 2024, NeuroSense Therapeutics Ltd. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC. This agreement
• NeuroSense Therapeutics Private Placement with Management — 6-K · Aug 7, 2024 Risk: medium
  On August 6, 2024, NeuroSense Therapeutics Ltd. entered into a securities purchase agreement for a private placement offering. This offering included members of
• NeuroSense Therapeutics Reports Positive ALS Trial Biomarker Data — 6-K · Aug 1, 2024 Risk: medium
  On August 1, 2024, NeuroSense Therapeutics Ltd. announced positive biomarker data from its ALS Phase 2b clinical trial. The press release, furnished as Exhibit
• NeuroSense ALS Trial Shows Significant Survival Benefit — 6-K · Jul 9, 2024 Risk: medium
  On July 9, 2024, NeuroSense Therapeutics Ltd. announced positive results from its PARADIGM Phase 2b clinical trial for Amyotrophic Lateral Sclerosis (ALS). The
• NeuroSense Therapeutics Shareholders Approve All Resolutions — 6-K · Jul 3, 2024 Risk: low
  NeuroSense Therapeutics Ltd. held its Annual General Meeting of Shareholders on June 27, 2024. All resolutions presented to the shareholders, which were previou
• NeuroSense ALS Drug Shows Efficacy in PARADIGM Study — 6-K · Jul 1, 2024 Risk: medium
  On July 1, 2024, NeuroSense Therapeutics Ltd. announced statistically significant efficacy and survival benefits from its 12-month PARADIGM study for people wit
• NeuroSense Therapeutics Amends Warrant Agreement — 6-K · Jun 27, 2024 Risk: low
  On June 26, 2024, NeuroSense Therapeutics Ltd. amended a warrant agreement with an institutional investor. This amendment adjusts the "Redemption Right" and ext

Risk Profile

Risk Assessment: Of NRSNW's 47 recent filings, 0 were flagged as high-risk, 39 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Alon Ben-Noon

Top Tags

drug-development (12) · biotech (10) · als (8) · clinical-trial (7) · ALS (6) · capital-raise (4) · compliance (4) · alzheimers (3) · corporate-governance (3) · press-release (3)

Key Numbers

• Topline Results: Q1 2026 — Expected timeframe for the release of results from the RoAD study
• Ordinary Shares: 333,334 — Number of shares sold in private placement
• Data analysis period: 18-month — Duration of the analyzed data from the PARADIGM study.
• Statistical significance: p=0.03 — Indicates a statistically significant effect in the analysis.
• Relative difference in decline: 28% — Favored patients receiving PrimeC, indicating potential efficacy.
• ALS Patients on PrimeC: 20% — Percentage of Phase 2a patients continuing treatment for over 5.5 years.
• Long-Term Treatment Duration: 5.5 years — Minimum duration of PrimeC treatment for a subset of patients.
• Fiscal Year End: 2024 — The period covered by the annual report.
• SEC File Number: 001-41084 — The company's SEC filing identification number.
• Study Duration: 18-month — Duration of the PARADIGM Phase 2b study
• Minimum Stockholders' Equity: $2.5 million — This is the threshold NeuroSense Therapeutics failed to meet, leading to the Nasdaq non-compliance notice.
• Potential Capital: $15 million — Maximum amount NeuroSense can raise through the equity purchase agreement with Yorkville.
• Agreement Term: 36 months — The duration over which NeuroSense can utilize the standby equity purchase facility.
• Dosing Period: 18-month — Duration of the completed ALS clinical trial dosing
• Toxicity Study Duration: 9-month — Length of the non-rodent toxicity study

Related Companies

NRSN · NSRS · NRPH

Frequently Asked Questions